Robert Booth

Dr. Robert F.
Booth is an Independent Non-Executive Director at Summit Therapeutics, Inc., an Advisor at Prime Movers Lab LLC and an Executive Chairman at Ab Initio Biotherapeutics, Inc. He is on the Board of Directors at Summit Therapeutics, Inc., Acurex Biosciences Corp., Galleon Pharmaceuticals, Inc., Glialogix, Inc. and Thryv Therapeutics, Inc. Dr. Booth was previously employed as an Independent Director by CymaBay Therapeutics, Inc., an Executive Chairman by CuraSen Therapeutics, Inc., an Independent Director by Pharmacyclics LLC, an Operating Partner by TPG Partners LLC, a Chief Executive Officer & Director by Virobay, Inc., a Vice President by Applera Corp., a Chief Scientific Officer by Celera Corp., a Chief Scientific Officer by Celera Genomics Group, a Senior VP-Central Research & Development by Roche Bioscience, a Senior Vice President by Roche Palo Alto LLC, a SVP-Inflammatory & Viral Diseases Business Unit by Hoffmann-La Roche, Inc., a Senior Vice President by Roche Pharmaceuticals, Inc., a Section Head by Searle Research & Development, and a Section Head by Wellcome Research Laboratories.
He received his undergraduate degree from the University of London, a doctorate degree from the University of London and a doctorate degree from St Bartholomew's Hospital Medical College.